John C.M. Farquhar Sells 22,562 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the sale, the chief executive officer directly owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. This trade represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Heartflow Stock Performance

NASDAQ HTFL traded down $1.99 during trading on Tuesday, reaching $27.30. 2,297,584 shares of the stock traded hands, compared to its average volume of 1,549,832. Heartflow, Inc. has a fifty-two week low of $25.38 and a fifty-two week high of $41.22. The firm’s 50-day moving average is $30.26.

Institutional Trading of Heartflow

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. TFC Financial Management Inc. acquired a new position in Heartflow during the third quarter worth $40,000. Legal & General Group Plc bought a new stake in Heartflow during the 3rd quarter worth about $59,000. Strs Ohio acquired a new position in shares of Heartflow during the 4th quarter worth about $99,000. Y Intercept Hong Kong Ltd bought a new position in shares of Heartflow in the 3rd quarter valued at about $234,000. Finally, Staley Capital Advisers Inc. acquired a new stake in shares of Heartflow in the fourth quarter valued at about $204,000.

Analyst Ratings Changes

Several research firms have weighed in on HTFL. Stifel Nicolaus lifted their target price on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company began coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group raised their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.